Genitourinary Cancers

Robert H. Weiss, MD, from the UC Davis Comprehensive Cancer Center, discusses peroxisome PPAR-alpha as a possible new treatment target for patients with renal cell carcinoma.

William C. Huang, MD, from the New York University Langone Medical Center, discusses findings from a SEER database analysis that compared surveillance to surgical resection in elderly patients with small renal masses.

Axitinib did not demonstrate superiority over sorafenib as first-line therapy for patients with metastatic renal cell carcinoma, on the endpoint of progression-free survival.

Combination targeted therapy did not significantly extend progression-free survival compared with single-agent bevacizumab in patients with advanced renal cell carcinoma.

Robert J. Motzer, MD, from Memorial Sloan-Kettering Cancer Center, discusses the overall survival results from the phase III TIVO-1 study that compared tivozanib to sorafenib in patients with renal cell carcinoma.

Deepak A. Kapoor, MD, president of the Large Urology Group Practice Association, discusses the implications of a large study looking at the detection of prostate cancer using prostate biopsies.

When the founding partners of Chesapeake Urology Associates (CUA) in Maryland decided to merge their practices, Sanford J. Siegel, MD, CUA's president and CEO, drew inspiration from another consolidation process.

Judd W. Moul, MD, from the Duke Cancer Institute, comments on practice trends in urologic cancer care and the advantages and disadvantages of his institution's multidisciplinary prostate cancer clinic.

Srikala Sridhar, MD, MSc, from the University of Toronto, Canada, discusses the results of a single arm phase II trial examining nab-paclitaxel as a secondary treatment for urothelial cancer.

Nab-paclitaxel might offer some hope for patients with advanced urothelial cancer, an area that has lagged behind the rapid growth in available therapies for other genitourinary cancers.

As many of us are keenly aware, the coming 12 months present some very challenging times in the medical community.

A panel of experts provides their thoughts on the USPSTF PSA screening recommendations, and how this widely publicized health message has impacted their urology practices.